Augustine Therapeutics N.V. announced that it will receive a round of funding on June 26, 2024.

On the same day, the company has received ?17 million in its first tranche, led by new investor, Asabys Partners. The tranche included participation from new investors, Eli Lilly and Company, Cmt Research Foundation, returning investors, AdBio Partners, V- Bio Ventures, VIB BV, Gemma Frisius Fonds NV, and Participatiemaatschappij Vlaanderen NV. As part of the transaction, Clara Campàs from Asabys Partners will join the company's board of directors.